06.03.2025 |
BioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe
Related items
26.10.2026
Key HighlightsThe peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in rats and…
22.10.2026
Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for…